- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04106362
Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With HPV Positive, KRAS-Variant Stage III-IV Oropharyngeal Squamous Cell Carcinoma
Randomized Phase II Trial of Radiotherapy With Concurrent Cisplatin +/- Concurrent Cetuximab for HPV-Positive Oropharyngeal Squamous Cell Carcinoma (OPSCC) in KRAS-Variant Patients
Study Overview
Status
Conditions
- Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- Pathologic Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- KRAS Protein Variant
Detailed Description
PRIMARY OBJECTIVES:
I. To determine the efficacy of radiation therapy with concurrent cisplatin combined with concurrent cetuximab in KRAS-variant oropharyngeal squamous cell carcinoma (OPSCC) patients in terms of overall survival (OS) at 2 years.
SECONDARY OBJECTIVES:
I. To determine the efficacy of radiation therapy with concurrent cisplatin combined with concurrent cetuximab in KRAS-variant OPSCC patients in terms of patterns of failure at 6 months and 2 years.
II. To determine the efficacy of radiation therapy with concurrent cisplatin combined with concurrent cetuximab in KRAS-variant OPSCC patients in terms of progression-free survival (PFS) at 2 years.
III. To determine the efficacy of radiation therapy with concurrent cisplatin combined with concurrent cetuximab in KRAS-variant OPSCC patients in terms of locoregional control (LRC) at 2 years.
IV. To determine the efficacy of radiation therapy with concurrent cisplatin combined with concurrent cetuximab in KRAS-variant OPSCC patients in terms of distant metastasis-free survival (DMFS) at 2 and 5 years.
V. To determine the efficacy of radiation therapy with concurrent cisplatin combined with concurrent cetuximab in KRAS-variant OPSCC patients in terms of OS at 5 years.
VI. To determine the safety of radiation therapy with concurrent cisplatin combined with concurrent cetuximab in KRAS-variant OPSCC patients in terms of acute toxicity profiles at the end of radiation, at 1 month, and at 6 months.
VII. To determine the safety of radiation therapy with concurrent cisplatin combined with concurrent cetuximab in KRAS-variant OPSCC patients in terms of late toxicity profiles at 1 and 2 years.
VIII. To determine the safety of radiation therapy with concurrent cisplatin combined with concurrent cetuximab in KRAS-variant OPSCC patients in terms of patient-reported swallowing outcomes at 6 months and 1 and 2 years.
IX. To assess the predictive value of fludeoxyglucose (FDG)-positron emission tomography (PET) at 10-14 weeks post-treatment.
X. To assess the predictive value of additional blood and tissue biomarkers for disease outcomes at 2 years.
EXPLORATORY OBJECTIVES:
I. To evaluate the impact of cetuximab on the immune response as well as treatment outcome and toxicity.
II. To evaluate biomarkers for immune response in HPV-associated OPSCC through saliva and blood samples to be collected prior to treatment and at each follow-up visit.
III. To evaluate for additional checkpoint targets through tumor tissue taken at the time of initial biopsy and profiled for tumor infiltrating lymphocytes, activation markers, and antigen-specific T-cell receptor (TCR) utilization/diversity.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Beginning on day 0, patients undergo radiation therapy over 6 weeks for a total of 35 fractions. Patients also receive cisplatin intravenously (IV) over 1-2 hours on days 0 and 21.
ARM II: Patients receive cetuximab IV over 120 minutes 5-7 days prior to start of radiation therapy and then IV over 60 minutes weekly on Monday or Tuesday for 7 weeks. Patients also undergo radiation therapy and receive cisplatin as in Arm I.
After completion of study treatment, patients are followed up at 2-4 weeks, every 12 weeks for 2 years, and then every 3-12 months for up to 5 years.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90095
- UCLA / Jonsson Comprehensive Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Written informed consent obtained from the patient/legal representative prior to performing any protocol-related procedures, including screening evaluation
- Newly diagnosed, untreated, biopsy-proven HPV+ squamous cell carcinoma of the oropharynx. Cytologic diagnosis from a cervical lymph node is sufficient in the presence of clinical evidence of a primary tumor in the oropharynx. Clinical evidence should be documented, may consist of palpation, imaging, or endoscopic evaluation and should be sufficient to estimate the size of the primary (for T stage). HPV-positivity will be defined as tumors that are p16-positive by immunohistochemistry
- Selective stage III-IV disease (T3-T4 or N2-N3 disease) by American Joint Committee on Cancer (AJCC) 8th edition as determined by a computed tomography (CT) scan or magnetic resonance imaging (MRI) of the head and neck, CT neck, chest, abdomen, pelvis or a PET =< 6 weeks of registration
- Confirmation of KRAS-variant status as assessed by genotyping from a cheek swab sample at MiraDx
Lifetime cumulative smoking history of < 10 pack-years. The cumulative total of the number of pack-years during each period of active smoking is the lifetime cumulative history
- Note: Investigators are discouraged from enrolling patients with a history of very sustained use (such as several years or more) of non-cigarette tobacco products alone given that the effect of non-cigarette tobacco products on the survival of patients with p16-positive oropharyngeal cancers is undefined
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 ? 1 within 60 days prior to registration
- Hemoglobin >= 9 g/dL (5.58 mmol/L) (within 2 weeks prior to registration)
- Absolute neutrophil count (ANC) >= 1500/uL (cells/mm^3) (within 2 weeks prior to registration)
- Platelet count >= 100,000/uL (cells/mm^3) (within 2 weeks prior to registration)
- Total bilirubin =< 1.5 mg/dL (25.65 umol/L) or =< 3.0 mg/dL if the patient has a history of Gilbert?s disease (within 2 weeks prior to registration)
- Aspartate transaminase (AST)/alanine transaminase (ALT) =< 2 x the institutional upper limit of normal (ULN) (within 2 weeks prior to registration)
- Serum creatinine =< 1.5 x institutional ULN OR creatinine clearance (measured via 24-hour urine collection) >= 50 ml/min (that is, if serum creatinine is > 1.5 times the ULN, a 24-hour urine collection to calculate creatinine clearance must be performed) (within 2 weeks prior to registration)
- Female subjects must either be of non-reproductive potential (i.e., post-menopausal by history: >= 60 years old and no menses for at least 1 year without an alternative medical cause, OR history of hysterectomy, OR history of bilateral tubal ligation, OR history of bilateral oophorectomy) or must have a negative serum pregnancy test within 7 days prior to enrollment
- Female subjects of child bearing potential and male subjects with partners of child bearing potential must agree to adequate contraceptive measures (hormonal or barrier methods) during treatment and for 2 months after the last dose of cetuximab
- Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment, scheduled visits, and examinations including follow up
Exclusion Criteria:
- Patients with biopsy-proven metastatic, HPV-negative, KRAS-variant negative, or recurrent head and neck squamous cell carcinoma (HNSCC)
- Patients with primary site of tumor outside of the oropharynx, specifically of the oral cavity, salivary glands, nasal cavity, paranasal sinuses, larynx, hypopharynx, or nasopharynx
- Patients with prior radiation therapy (RT) that would result in overlap of radiation therapy treatment fields (superficial x-ray of skin lesions excluded)
- Gross total excision (ex. tonsillectomy) of the primary tumor; however, partial removal of the tumor to alleviate an impending airway obstruction does not make the patient ineligible. Initial surgical treatment, excluding diagnostic biopsy of the primary site or nodal sampling of neck disease, as well as radical or modified neck dissection is not permitted
- Prior systemic chemotherapy or biologic therapy for the study cancer; note that prior chemotherapy or biologic therapy for a different cancer is allowable
- Prior therapy that specifically and directly targets the EGFR pathway
History of another primary invasive malignancy except for:
- Malignancy treated with curative intent and with no known active disease >= 3 years before the first dose of study drug and of low potential risk for recurrence
- Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
- Adequately treated low risk prostate cancer without evidence of disease
- Adequately treated carcinoma in situ without evidence of disease e.g., cervical cancer in situ, and ductal breast carcinoma in situ (DCIS)
- History of infusion reaction or hypersensitivity to cetuximab OR allergic reactions attributed to compounds of chemical or biologic composition similar to those of cetuximab
- Documented uncontrolled intercurrent illness or co-morbidity including, but not limited to, ongoing or active bacterial or fungal infection requiring intravenous antibiotics, uncontrolled congestive heart failure, cardiomyopathy, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition, or psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the subject to give written informed consent
- Female subjects who are pregnant or breastfeeding as well as male or female patients of reproductive potential who are not employing an effective method of birth control
- Patients with clinically relevant coronary artery disease or history of myocardial infarction in the last 12 months or high-risk of uncontrolled arrhythmia or uncontrolled cardiac insufficiency
- Patients with uncontrolled or poorly-controlled hypertension (> 180 mmHg systolic or > 130 mmHg diastolic)
- Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results
- Involvement in the planning and/or conduct of the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Arm I (radiation therapy, cisplatin)
Beginning on day 0, patients undergo radiation therapy over 6 weeks for a total of 35 fractions.
Patients also receive cisplatin IV over 1-2 hours on days 0 and 21.
|
Ancillary studies
Other Names:
Ancillary studies
Given IV
Other Names:
Undergo radiation therapy
Other Names:
|
Experimental: Arm II (cetuximab, radiation therapy, cisplatin)
Patients receive cetuximab IV over 120 minutes 5-7 days prior to start of radiation therapy and then IV over 60 minutes weekly on Monday or Tuesday for 7 weeks.
Patients also undergo radiation therapy and receive cisplatin as in Arm I.
|
Ancillary studies
Other Names:
Ancillary studies
Given IV
Other Names:
Undergo radiation therapy
Other Names:
Given IV
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival (OS)
Time Frame: From time of randomization to death due to any cause, assessed at 2 years
|
OS will be estimated in each study arm by Kaplan-Meier estimate.
Summaries of the number and percentage of patients who have died, are still in survival follow-up, are lost to follow-up and have withdrawn consent will be provided along with median OS.
Furthermore, a binomial test of proportions will be used to test difference in 2-year OS between the two arms.
Exact tests and continuity correction strategies will be considered when appropriate.
|
From time of randomization to death due to any cause, assessed at 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Primary tumor control
Time Frame: Up to 5 years
|
Will be determined by Response Evaluation Criteria in Solid Tumors version (v).
1.1.
Kaplan-Meier estimate will be used to describe primary control rate for each arm.
Furthermore, log-rank test will be used to test the difference between primary tumor control between the two arms.
|
Up to 5 years
|
Locoregional recurrence rate
Time Frame: Up to 5 years
|
Will be determined by surveillance imaging, with failure defined as appearance of new disease in the head and neck from the date of randomization.
Kaplan-Meier estimate will be used to describe locoregional recurrence rate for each arm.
Furthermore, log-rank test will be used to test difference in locoregional recurrence rates between the two arms.
|
Up to 5 years
|
Acute toxicity
Time Frame: Up to 5 years
|
Will be evaluated using the Common Terminology Criteria for Adverse Events (CTCAE) v5.0.
The safety analysis set will be used for safety analyses.
The overall safety and tolerability will be assessed throughout the study period.
All adverse event (AE) data will be listed individually by treatment group and patient identifier.
|
Up to 5 years
|
Late toxicity
Time Frame: Up to 5 years
|
Will be evaluated using the CTCAE v5.0.
The safety analysis set will be used for safety analyses.
The overall safety and tolerability will be assessed throughout the study period.
All AE data will be listed individually by treatment group and patient identifier.
|
Up to 5 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Germline mutation prediction rate
Time Frame: Up to 5 years
|
Will assess if additional germline mutations predict rate of progression free survival (PFS), overall survival and toxicity.
Multivariate Cox proportional hazards models will be used to assess if the endpoint is a prognostic variable for PFS, OS after adjusting for treatment arms and other clinical variables.
Multivariate logistic regression model will be used to evaluate the association with toxicity.
|
Up to 5 years
|
Nonsynonymous mutational load and intratumoral heterogeneity clinical outcome predictions
Time Frame: Up to 5 years
|
Will assess if nonsynonymous mutational load and intratumoral heterogeneity are predictive markers for clinical outcome (progression-free survival, overall survival, and toxicity) using next generation sequencing of baseline and relapsed tumors.
Multivariate Cox proportional hazards models will be used to assess if the endpoint is a prognostic variable for PFS, OS after adjusting for treatment arms and other clinical variables.
Multivariate logistic regression model will be used to evaluate the association with toxicity.
|
Up to 5 years
|
Change in circulating lymphocytes
Time Frame: Baseline up to 5 years
|
Will assess changes to circulating lymphocytes including CD-8, T-regulatory cells, and myeloid suppressor cells before, during and after treatment and correlations with progression free-survival, overall survival and toxicity.
Multivariate Cox proportional hazards models will be used to assess if the endpoint is a prognostic variable for PFS, OS after adjusting for treatment arms and other clinical variables.
Multivariate logistic regression model will be used to evaluate the association with toxicity.
|
Baseline up to 5 years
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Robert K Chin, UCLA / Jonsson Comprehensive Cancer Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Pharyngeal Neoplasms
- Otorhinolaryngologic Neoplasms
- Head and Neck Neoplasms
- Pharyngeal Diseases
- Stomatognathic Diseases
- Otorhinolaryngologic Diseases
- Neoplasms, Squamous Cell
- Carcinoma
- Carcinoma, Squamous Cell
- Squamous Cell Carcinoma of Head and Neck
- Oropharyngeal Neoplasms
- Physiological Effects of Drugs
- Antineoplastic Agents
- Immunologic Factors
- Antibodies
- Cisplatin
- Immunoglobulins
- Antibodies, Monoclonal
- Antineoplastic Agents, Immunological
- Cetuximab
Other Study ID Numbers
- 19-000543
- NCI-2019-03636 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
-
Jonathan Schoenfeld, MD, MPHNaverisRecruitingHPV Positive Oropharyngeal Squamous Cell Carcinoma | Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC... and other conditionsUnited States
-
Jonsson Comprehensive Cancer CenterAstraZenecaTerminatedOropharyngeal Squamous Cell Carcinoma | Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Pathologic... and other conditionsUnited States
-
Ohio State University Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnClinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8 | Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma... and other conditionsUnited States
-
National Cancer Institute (NCI)RecruitingClinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Pathologic Stage III HPV-Mediated (p16-Positive)...United States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedClinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Pathologic Stage I HPV-Mediated (p16-Positive)... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingClinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Stage III Hypopharyngeal Carcinoma AJCC v8 | Stage III Laryngeal Cancer AJCC v8 | Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8 | Stage IV Hypopharyngeal Carcinoma AJCC v8 | Stage IV Laryngeal Cancer... and other conditionsUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)Active, not recruitingClinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Oropharyngeal Human Papillomavirus-Positive Squamous...United States
-
Mayo ClinicRecruitingClinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Oropharyngeal Human Papillomavirus-Positive Squamous...United States
-
National Cancer Institute (NCI)NRG OncologySuspendedOropharyngeal Squamous Cell Carcinoma | Squamous Cell Carcinoma | Basaloid Squamous Cell Carcinoma | Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Papillary Squamous Cell Carcinoma | Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC... and other conditionsUnited States, Canada
-
Mayo ClinicRecruitingOropharyngeal Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Stage III Oropharyngeal (p16-Negative)... and other conditionsUnited States
Clinical Trials on Quality-of-Life Assessment
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol Specific | Malignant NeoplasmUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)RecruitingChildhood Malignant NeoplasmUnited States, Canada, Puerto Rico, Australia, New Zealand
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedOvarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Germ Cell Tumor | Ovarian Sarcoma | Malignant Ovarian Epithelial Tumor | Ovarian Carcinosarcoma | Ovarian Brenner Tumor | Ovarian Mucinous... and other conditionsUnited States
-
Wake Forest University Health SciencesWithdrawnLung Metastases | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma
-
City of Hope Medical CenterNational Cancer Institute (NCI)Recruiting
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | COVID-19 InfectionUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | COVID-19 InfectionUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Neuropathy | COVID-19 InfectionUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingCervical Carcinoma | Endometrial Carcinoma | Vaginal Carcinoma | Malignant Female Reproductive System Neoplasm | Vulvar CarcinomaUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingMetastatic Colorectal Carcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 and other conditionsUnited States